Replies to post #115616 on Biotech Values

[DewDiligence]

While MRX is shoring up the generic threat to Solodyn, it just received a P-IV challenge on its other acne drug, Ziana:

http://www.reuters.com/article/2011/04/05/medicis-idUSL3E7F539320110405